Special Issue "Challenges and Opportunities for Effective Cancer Immunotherapies"
Deadline for manuscript submissions: closed (28 February 2021).
2. University of Melbourne, Parkville, Victoria, Australia
Interests: cancer immunology; CAR T cell therapy; tumor microenvironment
In recent years, immunotherapies have generated spectacular outcomes in the clinic and changed the treatment scheme for cancer patients. Adoptive cell therapy (ACT), including using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, and checkpoint blockade have emerged as the most effective treatments for certain cancers. The current challenge for cancer immunotherapies is that although some patients have benefited from the treatments, a number of the cancers are resistant. The purpose of this Special Issue is to understand treatment resistance mechanisms and explore new options to provide exciting opportunities for effective anticancer immunotherapies. This Special Issue welcomes reviews, as well as original research articles, by 30 November 2020.
Prof. Dr. Michael Kershaw
Dr. Clare Slaney
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- CAR T cells
- adoptive cell transfer